Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: A randomized, double-blind study

Cardiovascular Drugs and Therapy

Volumn 10, Issue 2, 1996, Pages 145-152

  Crijns, Harry J G M ^a   Gosselink, A T Marcel ^a   Lie, Kong I ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Atrial fibrillation; Cardioversion; Disopyramide; Propafenone

Indexed keywords

ANTIARRHYTHMIC AGENT; DISOPYRAMIDE; PROPAFENONE;

ADULT; AGED; ARTICLE; CARDIOVERSION; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RATE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RELAPSE; SINUS RHYTHM; SKIN ALLERGY; TIME; VISUAL IMPAIRMENT;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; CHRONIC DISEASE; DISOPYRAMIDE; DOUBLE-BLIND METHOD; ELECTRIC COUNTERSHOCK; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROPAFENONE;

EID: 0029977330     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00823592     Document Type: Article

References (30)

1. Härtel G, Louhija A, Konttinen A. Disopyramide in the prevention of atrial fibrillation after electroconversion. Clin Pharmacol Ther 1974;15:551-555.
2. Södermark T, Edhag O, Sjögren A, et al. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter: A multicenter study from Stockholm. Br Heart J 1975;37:486-492.
3. Rasmussen K, Wang H, Fausa D. Comparative efficiency of quinidine and verapamil in the maintenance of sinus rhythm after DC conversion of atrial fibrillation. A controlled clinical trial. Acta Med Scand 1981;645(Suppl):23-28.
4. Lloyd EA, Gersh BJ, Forman R. The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double-blind study comparing quinidine, disopyramide and placebo. S Afr Med J 1984;65:367-369.
5. Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986;57:124-127.
6. Karlson BW, Torstensson I, Abjörn C, Jansson SO, Peterson LE. Disopyramide in the maintenance of sinus rhythm after electrocardioversion of atrial fibrillation. A placebo controlled one-year follow-up study. Eur Heart J 1988;9:284-290.
7. Juul-Möller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990;82:1932-1939.
8. Karlson BW, Herlitz J, Edvardsson N, Olsson SB. Prophylactic treatment after electroconversion of atrial fibrillation. Clin Cardiol 1990;13:279-286.
9. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. Circulation 1990;82:1106-1116.
10. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992; 20:527-532.
11. Connoly SJ, Kates RE, Lebsack CS, Echt DS, Mason JW, Winkle RA. Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. Am J Cardiol 1983;57:1208-1213.
12. Podrid PJ, Lown BL. Propafenone: A new agent for ventricular arrhythmia. J Am Coll Cardiol 1984;4:117-125.
13. Connoly SJ, Mulji AS, Hoffert DL, Davis C, Shragge BW. Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery. J Am Coll Cardiol 1987;10:1145-1148.
14. Kerr CR, Klein GJ, Axelson JE, Cooper JC. Propafenone for prevention of recurrent atrial fibrillation. Am J Cardiol 1988;61:914-916.
15. Hammill SC, Wood DL, Gersh BJ, Osborn MJ, Holmes DR. Propafenone for paroxysmal atrial fibrillation. Am J Cardiol 1988;61:473-474.
16. Antman EM, Beamer AD, Cantillon C, McGowan N, Goldman L, Friedman PL. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988;12:1005-1011.
17. Porterfield JG, Porterfield LM. Therapeutic efficacy and safety of oral propafenone for atrial fibrillation. Am J Cardiol 1989;63:114-116.
18. Connoly SJ, Hoffert DL. Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol 1989; 63:817-819.
19. Antman EM, Beamer AD, Cantillon C, McGowan N, Friedman PL. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: A staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990;15:698-707.
20. Kyles AE, Murdock CJ, Yeung-Lai-Wah JA, Vorderbrugge S, Kerr CR. Long-term efficacy of propafenone for prevention of atrial fibrillation. Can J Cardiol 1991;7:407-409.
21. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993;71: 558-563.
22. Van Gelder IC, Crijns HJGM, Van Gilst WH, De Langen CDJ, Van Wijk LM, Lie KI. Effects of flecainide on the atrial defibrillation threshold. Am J Cardiol 1989;63: 112-114.
23. Van Gelder IC, Crijns HJGM, Van Gilst WH, Van Wijk LM, Hamer HPM, Lie KI. Efficacy and safety of flecainide in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989;64:1317-1321.
24. Gosselink ATM, Crijns HJGM, Van Gelder IC, Hillege H, Wiesfeld ACP, Lie KI. Efficacy and safety of low dose amiodarone for long-term maintenance of sinus rhythm after electrical cardioversion of refractory chronic atrial fibrillation or flutter. JAMA 1992;267:3289-3293.
25. Flecainide-Quinidine Research Group. Flecainide versus quinidine for treatment of chronic ventricular arrhythmias. Circulation 1983;67:1117-1123.
26. Robertson RE, Miller HC. Extreme tachycardia complicating the use of disopyramirle in atrial flutter. Br Heart J 1980;44:602-603.
27. Timm CT, Knowlton AA, Battinelli NJ, Falk RH. Flecainide for heart rate control in atrial fibrillation. J Am Coll Cardiol 1989;13:164A.
28. Podrid PJ, Schoeneberger A, Lown B. Congestive heart failure caused by oral disopyramide. N Engl J Med 1980; 302:614-617.
29. Hoffmeister HM, Hepp A, Seipel L. Negative inotropic effects of class I antiarrhythmic drugs: Comparison of flecainide with disopyramide and quinidine. Eur Heart J 1987;8: 1126-1132.
30. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321: 406-412.